Our results showed that the growth of human cervical cancers was markedly suppressed by MTCH1 deficiency, Sorafenib treatment and MTCH1 deficiency + Sorafenib treatment (Fig. 6C). The gene discussed is MTCH1; the disease is cervical carcinoma.